Showing 2664 results
- Media Release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
- Media Release /Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
- Key Release /Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
- Key Release /Bertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
- Media Release /Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
- Key Release /Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
- Media Release /EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
- Media Release /Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
- Media Release /Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
- Key Release /Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…